AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of $6.78 million. The enterprise value is $7.06 million.
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025, after market close.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM ImmunoTech has 764,238 shares outstanding. The number of shares has increased by 25.35% in one year.
| Current Share Class | 764,238 |
| Shares Outstanding | 764,238 |
| Shares Change (YoY) | +25.35% |
| Shares Change (QoQ) | +9.87% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 645,250 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 46.44 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 48.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.26
| Current Ratio | 0.26 |
| Quick Ratio | 0.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.72 |
Financial Efficiency
Return on equity (ROE) is -3,138.91% and return on invested capital (ROIC) is -322.63%.
| Return on Equity (ROE) | -3,138.91% |
| Return on Assets (ROA) | -98.37% |
| Return on Invested Capital (ROIC) | -322.63% |
| Return on Capital Employed (ROCE) | 501.76% |
| Revenue Per Employee | $6,348 |
| Profits Per Employee | -$661,217 |
| Employee Count | 23 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.76 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 60,220 |
Short Selling Information
| Short Interest | 3.17M |
| Short Previous Month | 3.41M |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.10 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of $146,000 and -$15.21 million in losses. Loss per share was -$24.84.
| Revenue | 146,000 |
| Gross Profit | 113,000 |
| Operating Income | -17.66M |
| Pretax Income | n/a |
| Net Income | -15.21M |
| EBITDA | -17.41M |
| EBIT | -17.66M |
| Loss Per Share | -$24.84 |
Full Income StatementBalance Sheet
The company has $2.25 million in cash and $2.52 million in debt, giving a net cash position of -$275,000 or -$0.36 per share.
| Cash & Cash Equivalents | 2.25M |
| Total Debt | 2.52M |
| Net Cash | -275,000 |
| Net Cash Per Share | -$0.36 |
| Equity (Book Value) | -3.86M |
| Book Value Per Share | -5.34 |
| Working Capital | -7.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$12.43 million and capital expenditures -$18,000, giving a free cash flow of -$12.45 million.
| Operating Cash Flow | -12.43M |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -12.45M |
| FCF Per Share | -$16.29 |
Full Cash Flow StatementMargins
| Gross Margin | 77.40% |
| Operating Margin | -12,093.84% |
| Pretax Margin | -10,416.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.35% |
| Shareholder Yield | -25.35% |
| Earnings Yield | -224.30% |
| FCF Yield | -183.65% |
Analyst Forecast
The average price target for AIM ImmunoTech is $2.75, which is -66.87% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.75 |
| Price Target Difference | -66.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 270.24% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 12, 2025. It was a reverse split with a ratio of 0.01:1.
| Last Split Date | Jun 12, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.01:1 |
Scores
AIM ImmunoTech has an Altman Z-Score of -106.24 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -106.24 |
| Piotroski F-Score | 3 |